Vall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease
Vall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease

Next Monday, November 19, Vall d’Hebron will hold a seminar focused on Lysosomal Rare Disorders: Focus on Fabry Disease. The seminar is part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at

LEARN MORE
VHIR researchers receive European funding for liver disease research
VHIR researchers receive European funding for liver disease research

Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver Diseases group at VHIR, have received funding for a European research project in the Joint Call for transnational projects in nanomedicine, within the framework of the European network

LEARN MORE
The EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated
The EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated

The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies of the Biomedical Research Center Network on Rare Diseases (CIBERER), the Genetic Service and the Hospital de Sant Pau

LEARN MORE
CIBBIM Nanomedicine awarded at the National Congress of Paediatric Nephrology
CIBBIM Nanomedicine awarded at the National Congress of Paediatric Nephrology

Pre-doctoral researcher Mónica Vall, from the research group in Renal Physiopathology – CIBBIM Nanomedicine led by Dr. Anna Meseguer, won the prize for the best poster – short communication from the XLIII National Congress of Paediatric Nephrology, held in Valencia, for her work “Establishment of the protocol for isolating urinary exosomes in patients with familial

LEARN MORE
Dr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society
Dr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society

Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will occupy this position for two years with Dr. Beatriz Salinas Rodriguez, of the Health Research Institute

LEARN MORE
A new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the most active research projects in Nanomedicine of Europe
A new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the most active research projects in Nanomedicine of Europe

For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group. Addressing and Pharmacological Release that leads Dr. Simó Schwartz Jr. The EVO-NANO project aims to develop a virtual simulator, called

LEARN MORE
The EVO-NANO project will allow testing the behavior of nanoparticles within a tumor
The EVO-NANO project will allow testing the behavior of nanoparticles within a tumor

The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project aims to develop a virtual simulator, called NanoDoc, which will allow testing the behavior of nanoparticles within a tumor and with

LEARN MORE
April, Fabry disease awareness month
April, Fabry disease awareness month

The Fabry International Network (FIN) association has established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry disease is a metabolic disease that is produced by a deficiency of the Lysosomal enzyme Alpha galactosidase. It is transmitted on

LEARN MORE
Dr. Simó Schwartz Jr, appointed editorial Board member of the Precision Nanomedicine journal
Dr. Simó Schwartz Jr, appointed editorial Board member of the Precision Nanomedicine journal

In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the editorial board of the journal. The rest of editors belong to the United States, Australia,

LEARN MORE
The team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing
The team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing

One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz Jr, director of the CIBBIM-nanomedicine has managed to create a micelle formed

LEARN MORE
The Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System
The Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System

This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or histological processing services for agents with therapeutic or diagnostic activity, especially those with a nanotechnology base. The certification audit was carried out in May 2017 by

LEARN MORE
Asdent donates more than 114,000 euros for the investigation of Dent’s disease in Vall d’Hebron
Asdent donates more than 114,000 euros for the investigation of Dent’s disease in Vall d’Hebron

Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and characterized by alterations of the proximal renal tubule that result in proteinuria, hypercalciuria and nephrocalcinosis. The patients expel in

LEARN MORE
Proven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer
Proven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer

The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and specificity of targeted therapy against cancer through the use of polyurethane-polyurea nanocapsules (PUUa), a nanoparticle with a proven targeted

LEARN MORE
Proven that a protein produced by the kidney could become a therapeutic target for the metabolic syndrome
Proven that a protein produced by the kidney could become a therapeutic target for the metabolic syndrome

A study led by Dr. Anna Meseguer, chief of the group of research CIBBIM-Nanomedicine Renal Pathophysiology of the Vall d’Hebron Research Institute (VHIR), has showed the role of the KAP protein in the control of the development of the metabolic syndrome produced by following a diet rich in fats. The creation of a model based

LEARN MORE
Learned lessons from a primary immunodeficiency: a study by Dr. Joan Sayos
Learned lessons from a primary immunodeficiency: a study by Dr. Joan Sayos

Last September, the journal of Immunology published a new article in the series “The Pillars of Immunology”, which reminds the classics that have promoted the knowledge of modern immunology. In this case, the study published has been based in the paper published in 1998 by Dr. Joan Sayos, head of the research group CIBBIM –

LEARN MORE
6,8€ Million Granted to nTRACK Horizon 2020 Project, in which VHIR participates, to study multimodal nanoparticles as contrasts imaging agents for muscle regeneration
6,8€ Million Granted to nTRACK Horizon 2020 Project, in which VHIR participates, to study multimodal nanoparticles as contrasts imaging agents for muscle regeneration

The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project, which will officially be launched on the 16th of October in Barcelona. The goal of the nTRACK project is to develop a highly sensitive multimodal nano-imaging agent in compliance with current regulatory framework. It will enable non-invasive, quantitative and longitudinal

LEARN MORE
CaixaImpulse selects a VHIR project to combat multiresistant infections
CaixaImpulse selects a VHIR project to combat multiresistant infections

El projecte ThermoShot™-FlashShot™: Nova tecnologia per combatre les infeccions multiresistents o les produïdes per dispositius mèdics que produeixen biopel·lícules forma part dels 23 treballs seleccionats en la tercera convocatòria del Programa CaixaImpulse. Està liderat pel Dr. Joan Gavaldà Santapau, coordinador del Laboratori de Resistències Antibiòtiques del Grup de Recerca en Malalties Infeccioses de Vall d’Hebron

LEARN MORE
NANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS
NANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS

NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, including the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of

LEARN MORE
The EU-NCL network will support a project of nanomedicine for prostate cancer
The EU-NCL network will support a project of nanomedicine for prostate cancer

The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. The project is coordinated by Dr. Simó Schwartz Jr, director of CIBBIM-nanomedicine, and Dr. Ibane Abasolo, from CIBBIM-Nanomedicine. Drug Delivery and Targeting group at VHIR, and Dr. María Jesús Vincent,

LEARN MORE
Nanoparticles against cancer in the Live Research Fair
Nanoparticles against cancer in the Live Research Fair

Can we improve the treatment of cancer with the help of nanoparticles? How can we help improve the effectiveness of a drug? Which treatment works best? And how can we test it? These are some of the questions that the group if Functional Validation and Preclinical Research (FVPR) has responded, from the research group CIBBIM-Nanomedicine.

LEARN MORE
Tumour cells are dependent on fat to start metastasis
Tumour cells are dependent on fat to start metastasis

A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Natureidentifies metastasis-initiating cells through a specific marker, namely the protein CD36. This protein, which is found in the membranes of tumour cells, is responsible for taking up fatty acids. CD36 activity and dependence

LEARN MORE
VHIR participates in a European project against Fabry disease
VHIR participates in a European project against Fabry disease

The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, which aims the innovation and improvement in the treatment for Fabry disease, a rare condition X-linked which affects 1 in 7.000 people approximately. The project is awarded with 5,8 milion in the

LEARN MORE
Customized prosthesis made for patients by a digital planning platform
Customized prosthesis made for patients by a digital planning platform

The Oral and Maxillofacial Surgery Service at Vall d’Hebron University Hospital has a new tools to make the recovery of patients easier. Together with the company Avinent, this service developed a new digital planning platform, pioneer, which allows surgeons to prepare the intervention and also allows them to contact engineers and technical staff who design

LEARN MORE
The laboratory of Dr. Abasolo receives the visit of a future investigator
The laboratory of Dr. Abasolo receives the visit of a future investigator

Artur Aymar is sure he wants to study Biomedical Engineering; for this reason, he is happy to perform the research work in one of the VHIR’s laboratories as it is the opportunity to learn first-hand “what kind of research takes place in a real lab”. Artur is 16 years old and he is studying 2nd

LEARN MORE
Dr. Simó Schwartz Jr has been appointed as a member of the advisory board of the EU-NCL
Dr. Simó Schwartz Jr has been appointed as a member of the advisory board of the EU-NCL

Dr. Simó Schwartz Jr, director of the CIBBIM-Nanomedicine of the Vall d’Hebron Institute of Research (VHIR), has been appointed as a member of the advisory board of the Nanomedicine Characterisation Laboratory (EU-NCL). Dr. Schwartz will collaborate with the EU-NCL defining the objectives as well as setting up the strategic plan and director plan. The EU-NCL

LEARN MORE
La Masia and the AECC promoting a solidarity oil for breast cancer research
La Masia and the AECC promoting a solidarity oil for breast cancer research

The Spanish Association Against Cancer (AECC) and La Masía have presented today the initiative “Aceite de Oliva Solidario” (Solidarity Olive Oil). The goal of the challenge – which starts today and ends on October 19, World Day Against Breast cancer – is to fund with 50,000 euros the breast cancer research project directed by Dr.

LEARN MORE
Asdent donates more than 120,000 euros to raise funds for the Dent’s disease at Vall d’Hebron
Asdent donates more than 120,000 euros to raise funds for the Dent’s disease at Vall d’Hebron

Nacho is a 6-year-old child who was diagnosed when he was 3 with the Dent’s disease; a rare untreatable disease which may result in renal failure. Since the diagnosis, his parents have not stop to reverse this situation getting researchers to investigate in order to curb the disease. Now, 3 years after the diagnosis, they

LEARN MORE
Dr. Simó Schwartz, Scientific, appointed president of the European Society for Nanomedicine (ESNAM)
Dr. Simó Schwartz, Scientific, appointed president of the European Society for Nanomedicine (ESNAM)

The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in nanomedicine, like NANBIOSIS, among members of the society and its utilities is also an object of ESNAM. This is intended to strengthen

LEARN MORE
VHIR brings nanomedicine to the Science Festival
VHIR brings nanomedicine to the Science Festival

The Vall d’Hebron Research Institute (VHIR) participated once again in the Science Festival, which this year has reached its 10th edition. Dr. Víctor Puntes, head of the group of Design and Pharmacodynamics of Nanoparticles, gave a talk, with two experiments, to explain the benefits of nanomedicine on the health of people. As the festival program

LEARN MORE
VHIR presented the results of three projects of the TV3’s Marathon 2010
VHIR presented the results of three projects of the TV3’s Marathon 2010

On Wednesday 15 June was held the Symposium on acquired spinal cord and brain injuries, in which have been presented the results of the 30 projects funded in the 2010 edition of the TV3 Marathon. Of these projects, three were carried out at the Vall d’Hebron Research Institute (VHIR). The Institute’s director, Dr. Joan Comella,

LEARN MORE
The Association for Familial Hypomagnesemia donates once again 15000 € for the research of this disease
The Association for Familial Hypomagnesemia donates once again 15000 € for the research of this disease

For the second year in a row, the Association for Information and Research of Familial Hipomagnesemia (Hipofam) has given 15000 euros to the research group on Renal Physiopathology of Vall d’hebron Research Institute (VHIR) to investigate this rare genetic disease. The funds have been collected through numerous charitable activities, such as paddle tennis tournaments, exhibitions

LEARN MORE
Dr. Schwartz Jr participates in a European nanomedicine project for pancreatic cancer
Dr. Schwartz Jr participates in a European nanomedicine project for pancreatic cancer

The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, called NoCanTher, which aims to develop treatments with nanomedicine for pancreatic ductal carcinoma. The project is awarded with 7 million euros in the Horizon 2020 program of the European Commission, and involves

LEARN MORE
Dr. Anna Meseguer receives grant from the American Association for Cancer Research
Dr. Anna Meseguer receives grant from the American Association for Cancer Research

Dr. Anna Meseguer, head of the Kidney Physiopathology group at the Vall d’Hebron Institute of Research (VHIR), has received the 2016 Research Grant for Immunotherapy in Kidney Cancer of the American Association for Cancer Research, endowed with 250,000$ for two years. Her research project, entitled “Could TIM-1 constitute a new target for renal carcinoma immunotherapy?”,

LEARN MORE
Taking care of your kidneys, and also of the youngest ones’
Taking care of your kidneys, and also of the youngest ones’

Renal disease, those that affect the kidneys are not an issue just for adults. Younger children also suffer. A reality that sometimes is hidden and has led to devote this year’s World Kidney Day to preventing diseases that affect children. Under the slogan Kidney Disease and Children, act quickly to prevent it, the Spanish Association

LEARN MORE
Dr Simó Schwartz Jr is appointed editor of the European Journal of Nanomedicine
Dr Simó Schwartz Jr is appointed editor of the European Journal of Nanomedicine

Dr Simó Schwartz Jr, director of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), has been appointed member of the editorial board of the European Journal of Nanomedicine. VHIR’s researcher will review some of the manuscripts submitted to the prestigious scientific journal for the next two years. The journal focuses on the spectrum from

LEARN MORE
Three VHIR researchers receive three important European grants
Three VHIR researchers receive three important European grants

Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR), have been granted with three important European projects. The first two

LEARN MORE
New methodology to improve the drug response of breast and colon cancer with nanomedicine
New methodology to improve the drug response of breast and colon cancer with nanomedicine

Researchers from the Drug Delivery and Targeting group of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VIHR), have evidenced that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. To be able to study the efficacy of the nanomedicines, researchers have developed a novel fluorescent model that allowed them to visualize

LEARN MORE
VHIR inaugurates the 2nd edition of the Master’s Degree in Translational Biomedical Research

On September 29th, Vall d’Hebron Institute of Research (VHIR) celebrated the opening day of the 2nd edition of the Official Master’s Degree in Translational Biomedical Research and the closing of the 1st edition, with the diploma award ceremony. Dr. Manel Esteller, director of the Cancer Epigenetics and Biology Program of the Bellvitge Biomedical Research Institute

LEARN MORE
VHIR receives two grants from the AECC to investigate stomach cancer and melanoma
VHIR receives two grants from the AECC to investigate stomach cancer and melanoma

The Vall d’Hebron Research Institute (VHIR) has received two projects in the last call of the Associación Española Contra el Cáncer (AECC) to investigate stomach cancer and malignant melanoma. The projects, worth 1,200,000 euros each, are led by Dr. Diego Arango, group leader of the Molecular Oncology Nanomedicine CIBBIM-VHIR, and Dr. Maria S. Soengas, from

LEARN MORE
The artist Josep Moscardó collaborates with VHIR by donating his Montjuïc Nit work
The artist Josep Moscardó collaborates with VHIR by donating his Montjuïc Nit work

“Montjuïc nit” is the artist’s Josep Moscardó personal perspective of a set of emblematyc areas of Barcelona such as Montjuïc Hill, the Olympic ring on Montjuïc, the Paral·lel or the Port. Moscardó has donated a silk-screen printing edition of his work with a handwritten signature and numbering in order to help fundraising for research on

LEARN MORE
VHIR researchers validate a new therapeutic target for colorectal cancer treatment
VHIR researchers validate a new therapeutic target for colorectal cancer treatment

Researchers from the Group of Molecular Oncology CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have validated a gene, called PPOX, as a new therapeutic target against colorectal cancer. Furthermore, this study opens the door to the validation of more targets, as PPOX is only one of the 966 genes that researchers have found overexpressed

LEARN MORE
VHIR researchers presented the results funded by the Marató of 2009 devoted to rare diseases
VHIR researchers presented the results funded by the Marató of 2009 devoted to rare diseases

On Monday afternoon, 20 research projects funded by La Marató 2009 devoted to rare diseases were presented in the 16th Symposium La Marató of TV3, at the Institut d’Estudis Catalans’ facilities. There were researchers from Vall d’Hebron, who had participated in three of the projects. Inhibition of the Notch’s pathway as a therapeutic target in

LEARN MORE
VHIR proposals for Sant Jordi
VHIR proposals for Sant Jordi

Here you have our three recommendations for this Sant Jordi’s Day: ‘En Roc al Planeta Mascareta’, ‘Nano-Oncology, the Turning Point’ and ‘Aians’. These three books are written by professionals from Vall d’Hebron Hospital. En Roc al Planeta Mascareta Roc is a kid who after escaping from the paws of a terrible dragoon (the disease), with

LEARN MORE
Possible new strategies to combat epithelial metastatic cancer have been described
Possible new strategies to combat epithelial metastatic cancer have been described

An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d’Hebron Research Institute (VHIR) includes the latest discoveries in the field of epithelial metastatic cancer and considers the possibility of opening new therapeutic fronts for

LEARN MORE